Trim 40-50% of GILD now; redeploy to 4.5%+ T-bills; $141.50 hard stop; Q3 as binary re-evaluation
Sell with 40-50% trim is the validated framework per 10/5 binding reflection; the 9/29 Hold at this exact setup produced -1.5%/-1.3% alpha and the 10/5 30% trim reproduced the hedged-middle failure mode (-0.8% alpha). The $141.50 stop (50 SMA, 0.75 ATR below current) provides structural break confirmation vs. Neutral's sub-2-ATR $138-140 stop which gets tagged on routine mean reversion. Rotation into 4.5%+ T-bills captures 223bps yield differential vs. GILD's 2.27% dividend with zero equity correlation through the Q3 catalyst. Price target of $141.50 equals the hard stop (intentionally — floor and stop are the same line).
| Position | Action |
|---|---|
| Current levels (~$144) | Trim 40-50% of existing GILD exposure |
| Bounce into $147-$150 (10 EMA / lower VWMA convergence) | Additional trims on any bounce |
| Residual position maintenance | Maintain 50-60% of benchmark weight |
| Daily close at or below $141.50 | Hard stop exit residual position |
GILD is a defensive compounder with fortress balance sheet ($9.77B FCF, 2.5x dividend coverage), underappreciated pipeline optionality (lenacapavir, oncology, seladelpar), and favorable macro tailwinds from defensive rotation in a high-rate environment—trading at a compressed multiple that creates an asymmetric entry.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $135.49 | bullish |
| close_50_sma | $143.24 | neutral |
| close_10_ema | $147.32 | bearish |
| rsi | 43.40 | neutral |
| macd | 0.64 | bearish |
| macds | 1.77 | bearish |
| macdh | -1.13 | bearish |
| boll | $148.06 | bearish |
| boll_ub | $154.39 | neutral |
| boll_lb | $141.72 | neutral |
| atr | $3.38 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: 50 SMA retest with MACD/RSI confirmation
Then: 50% scaled add
Hawkish Fed is a competitive moat for GILD, not a headwind—the macro framework must fit the asset class
↩ rebuts: “Bear's 'hawkish Fed caps DCF' thesis”
EV: +5.2:1 reward-to-risk on Target 3 ($157/52-week high); +1.6:1 on Target 1 ($148/10 EMA reclaim) · concedes: RSI at 43.40 is not oversold; MACD histogram is negative at -1.13; Revenue CAGR is only ~2-3%; Negative GAAP EPS of -$2.65 exists (though non-cash); Short-term technical signals are genuinely weak
GILD is a deteriorating technical setup with a patent cliff on its largest revenue driver, overhyped pipeline optionality, a yield trap versus risk-free alternatives, and balance sheet quality erosion from repeated M&A write-downs — creating asymmetric downside risk that makes SELL/UNDERWEIGHT the prudent position.
EV: Base case: $130 (-10% downside); Bear case: $115 (-20% downside); Bull case: $157 (+9% upside) · concedes: Defensive sectors do outperform cyclicals in late-cycle tightening environments (true, but relative outperformance, not absolute price appreciation); Lenacapavir's twice-yearly dosing is genuinely differentiated versus daily pills; Seladelpar has accelerated approval and competes in PBC, a rare disease with unmet need; Yescarta is genuinely the leading CAR-T in second-line large B-cell lymphoma indication; FCF generation is real at ~$9.77B annually; Goodwill at $8.3B is not impaired currently; Net debt has been declining; The HIV cure research program is unique across major pharma
→ vs conservative: Fundamental metrics (9.77B FCF, 0.33 beta, 38% payout ratio) are backward-looking; the 24-36 month patent cliff is a forward-looking, time-dated event that trailing cash flow does not protect against
→ vs conservative: 2.27% dividend yield creates a 223 basis point gap versus 4.5% risk-free rate; T-bills are a better risk-adjusted wait vehicle than a single-name equity with a patent cliff
→ vs conservative: 14.6 forward P/E with zero margin of safety on a company facing a quantified 2-3 year revenue cliff will see multiple compression or derating
→ vs neutral: Waiting for 200 SMA break, RSI above 50, and MACD histogram turning positive is lagging analysis; marginal buyer has already walked away as evidenced by price below VWMA, MACD bearish cross, and inability to reclaim 10 EMA
→ vs neutral: 200 SMA at 135.49 being intact is not a buy signal; it is a thin 6.5% air pocket that broke in April-June without concurrent structural pressure, unlike the current setup with patent cliff, rate headwind, and technical breakdown all simultaneous
| vwma | ~$149.55 | bearish |
Support: 143.24 · 141.72 · 135.49 | Resistance: 147.32 · 148.06 · 150.89 · 152.67
GILD exhibits a bifurcated technical picture: the long-term trend remains intact with price 6.5% above the 200 SMA ($135.49), but short-term momentum has rolled over decisively with MACD crossing below its signal line, histogram widening to -1.13, and price trading $5.32 below the volume-weighted moving average. The critical inflection sits at the 50 SMA ($143.24) — a failure here opens downside toward the lower Bollinger Band at $141.72, while reclaiming the 10 EMA at $147.32 would signal relief for bulls. The ATR of $3.38 suggests moderate volatility, with stops placed below the lower band representing roughly 0.75 ATR of risk.
Market Cap
$178.84 B
52-Week High
$157.29
52-Week Low
$112.82
Beta
0.332
Dividend Yield
2.27%
Forward P/E
14.58x
P/B
15.13x
PEG Ratio
2.15
EPS (TTM)
−$2.65
Forward EPS
$9.89
Free Cash Flow (TTM)
$9.77 B
Revenue FY2025
$29.442 B
Revenue FY2024
$28.754 B
Revenue FY2023
$27.116 B
Revenue FY2022
$27.281 B
Gross Profit FY2025
$23.208 B
Gross Margin
78.8%
R&D FY2025
$5.799 B
Operating Income (Adjusted) FY2025
$11.701 B
Operating Margin
39.7%
Net Income FY2025
$8.510 B
Diluted EPS FY2025
$6.78
Adjusted EBITDA FY2025
$14.809 B
Tax Rate
13.1%
Cash & ST Investments
$9.613 B
Goodwill
$8.314 B
Other Intangibles
$16.978 B
Total Assets
$59.023 B
Long-Term Debt
$22.129 B
Total Debt
$24.936 B
Net Debt
$17.372 B
Stockholders' Equity
$22.702 B
Current Ratio
1.27
Operating Cash Flow FY2025
$10.019 B
CapEx FY2025
$563 M
Free Cash Flow FY2025
$9.456 B
Dividends Paid FY2025
$4.003 B
Buybacks FY2025
$1.922 B
Net Debt/EBITDA
1.2x
FCF Yield
6.8%
Payout Ratio
38%
Strengths
Concerns
Gilead Sciences is a financially robust, low-beta pharmaceutical company with best-in-class free cash flow generation (~$9.5B annually, ~30%+ FCF margin) and a steadily growing dividend (2.27% yield, well-covered at ~38% payout). The company shows strong operational momentum with operating margins expanding from 33.7% to 39.7% over four years, driven by its dominant HIV franchise (Biktarvy), oncology assets (Trodelvy, Yescarta, Tecartus), and recent seladelpar acquisition. Reported GAAP earnings are heavily distorted by non-cash acquisition-related impairments (~$1.68B special charges in FY2025) and intangible amortization, resulting in negative TTM EPS of -$2.65 despite normalized earnings of ~$6.78 and forward EPS of $9.89. The balance sheet shows improving tangible book value and manageable leverage (Net Debt/EBITDA ~1.2x). Valuation is fair at Forward P/E ~14.6x and ~6.8% FCF yield, but the stock is near its 52-week high, supporting a HOLD stance with accumulation recommended on pullbacks toward the 200-day moving average (~$136-138).
Macro: The macro regime dominating the week is "higher-for-longer rates plus sticky inflation, but equity markets are shrugging it off near record highs." The 10-year Treasury yield touched its highest level since 2002 during September and posted its biggest monthly gain since 2022, though it has eased off highs following a cooler-than-expected inflation report and September jobs miss. The Fed is decisively hawkish: Polymarket prices 96% probability of zero rate cuts in 2026. Recession odds by year-end 2026 are priced at just 6% (down 2pp week-over-week). The Iran war is driving an inflation pulse through energy/supply-chain channels. Labor markets are cooling (September jobs miss) but not enough to force a dovish pivot. Mortgage rates at 7.58% are near 3-year highs, pressuring housing and consumer discretionary. Equity markets are experiencing a tech-led melt-up with S&P 500 and Nasdaq at record highs, driven by Nvidia/AMD leadership, while rate-sensitive cyclicals lag significantly.